ICMR study on long COVID
25 Aug 2023 6 mins Download PDF
ICMR study on long COVID
Why in the News?
A recent study was conducted by the Indian Council of Medical Research (ICMR) on the post Covid-19 conditions and its report has been recently published.
- The WHO estimates that 10 to 20 per cent of Covid patients develop prolonged symptoms.
Key findings of the Study:
-
- Nearly 6.5% people hospitalised with Covid-19 died in the following year.
- About 17.1% of the participants experienced post-Covid-19 conditions.
- The study defines “post Covid-19 conditions” as persistent or new onset of fatigue, breathlessness, or cognitive abnormalities.
- People were nearly three times more likely to die if they experienced these post-Covid-19 conditions.
- Even a single dose of the vaccine before the infection reduced the number of deaths in the one-year period by 60%.
- The factors that increased the risk of death following a Covid-19 infection later in the year were,
- Comorbidity- people with one comorbid condition were more than 9 times likely to die during the year following the infection.
- Age- people above the age of 60 years are 2.6 times more likely to die compared to other age groups and Children between the ages of 0 and 18 years were at a 5.6 times higher risk of death.
- Gender- Men were 1.3 times more likely to die compared to women.
- Long Covid can happen even in people who have had mild Covid-19.
About:
Coronavirus:
- The virus spreads mainly through close contact between people mainly through air transmission through small, liquid, virus-carrying particles that float through the air for longer periods of time and can be inhaled by others.
- The virus transmission via contaminated surface contact is markedly less efficient than airborne transmission.
- Biological changes in the virus can lead to mutations causing emergence of COVID-19 variants.
- COVID‑19 vaccine was developed to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID‑19.
- The vaccines were used in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19.
- COVID-19 vaccines approved for use in India include:
- Covaxin of M/s Bharat Biotech for age group of 6-12 and 12-18 years
- Sputnik -V of M/s Dr. Reddy’s Laboratories Ltd. (Importer)
- Sputnik -V of M/s Panacea Biotec Ltd
- Janssen - Johnson & Johnson (Importer)
- Janssen - M/s Biological E Limited
- ZyCoV-D of Zydus Cadila - age group >12 years
- Sputnik -V of M/s Hetero Biopharma Ltd
- Corbevax of Biological E. Limited - age groups 5-12, >12 and >18 years
- Covovax of M/s Serum Institute of India - age groups >12 and >18 years
- Moderna - M/s Cipla (Importer)
- SPUTNIK Light of M/s Dr. Reddy’s Lab. Ltd. (Importer)
- SPUTNIK Light of M/s Hetero Biopharma Ltd
- Lyophilized mRNA Vaccine for Injection (COVID-19) [HGCO-19] of M/s Gennova Biopharmaceuticals Limited
- BBV154 (iNCOVACC) - M/s Bharat Biotech
Related Article

Join Guru मार्गदर्शन ( Mentorship )
( First 5 Minutes Free )

Discuss Current Issues on Guru Forum
